The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report@ https://www.novaoneadvisor.com/report/sample/7886
Asthma and COPD Drugs Market Scope
|
Report Coverage |
Details |
|
Market Size in 2025 |
USD 39,566.00 Million |
|
Market Size by 2034 |
USD 59,562.82 Million |
|
Market Growth Rate from 2025 to 2034 |
CAGR of 4.65% |
|
Base Year |
2024 |
|
Forecast Period |
2025 to 2034 |
|
Segments Covered |
Diseases, Medication Class, Distribution Channel, and Region |
|
Regions Covered |
North America, Europe, Asia-Pacific, Latin America and Middle East & Africa |
The asthma and COPD drugs market is witnessing major growth contributed by increasing technological advancements, surging geriatric population, pollution, and increased smoking rate globally. In addition, there are various major trends transforming market growth such as the increasing prevalence of respiratory disorders, growing investments in drug development, and rising research and development activities by the government and private organizations.
One of the major opportunities driving the growth of the market is the ongoing expansion of healthcare infrastructure in the developing economies such as Asia Pacific, Africa, and the Middle East. Also, drugs like probiotics are gaining traction in the disease treatment as they strengthen the immune health via gut ecosystem and can be helpful in the treatment asthma.
The integration of AI in the market helps to offer individualized medication or treatment plans. The AI system analyses the vast amount of data gathered including genomics, clinical data, and proteomics which help to identify new medicinal marks. Furthermore, AI systems can monitor the timely impact of the drugs on patients and help physicians if some changes are required to reduce the charges and time associated with the treatment of COPD and asthma.
Market Trends
· Increasing public awareness: The major trend in the market is the surging public awareness regarding respiratory diseases. Many private and government organizations are making efforts to raise awareness regarding asthma and COPD among general populations, leading to market expansion further.
· Growing Adoption of Bioelectric Medicine: Bioelectric medicines are increasingly being developed by major players in the anti-asthmatics and COPD drugs markets. This medicine utilizes implantable, miniaturized devices which can change the electrical signals that travel over the nerves in the body like altered and irregular impulses that are found in many diseases.
· Combination Therapies: The treatment and efficacy of this disease are tackled with the medication of combination therapies. The advancement of combination therapies involves the integration of various classes of medications such as bronchodilators and corticosteroids which results in an enhanced therapeutic medication.
Segment Insights
By Disease Type Insight
The asthma segment dominated the asthma and COPD drugs market in 2024. The dominance of the segment can be attributed to the increasing number of asthma patients across the globe due to the surge in cigarette consumption that strengthens the asthma symptoms. Additionally, the surge in industrialization, especially in developing countries in the world has increased air pollution which directly affects the rising prevalence of Asthma disease among these countries.
· In April 2023, GlaxoSmithKline Plc announced that it had launched its new asthma spacer, the Breo AeroChamber Plus. The Breo AeroChamber Plus is a spacer that is designed to improve the delivery of Breo Ellipta, a dry powder inhaler.
The COPD segment is expected to grow at the fastest rate over the forecast period. The growth of the segment can be credited to the increasing incidence of COPD and its complexity along with the innovations in COPD treatment. Furthermore, the increasing emission of toxic gases and air pollution globally can contribute to the higher prevalence of this disease condition. Chronic obstructive pulmonary disease (COPD) is a disorder mainly caused by damage to certain parts of the lungs or the airways.
By Medication Class Insight
Combination drugs segment held the largest asthma and COPD drugs market share in 2024. The dominance of the segment can be driven by the reliability and effectiveness of combination therapies. The use of a combination of drugs and medications to treat an extensive category of diseases has rapidly increased in recent years. In addition, the increasing research and development initiatives coupled with the stringent government regulations can impact the segment's growth positively further.
The inhaled corticosteroids segment is estimated to grow at the fastest rate during the projected period. The growth of the segment is owing to the current developments in respiratory treatments. Inhaled corticosteroids can prevent asthma attacks while also enhancing overall lung function. They can also be utilized to treat other lung conditions like COPD. As compared to other types of drugs, these medications are effective in treating asthma and other respiratory diseases.
By Regional Insights
Presence of Major Pharmaceutical Market Players: North America to Sustain as a Leader
North America dominated the asthma and COPD drugs market in 2024. The dominance of the region can be attributed to the increasing incidence of asthma along with the strong presence of major pharmaceutical market players in the region. Moreover, the region also witnessing a rise in tobacco consumption in major countries such as Canada and the US can boost the market growth in the region soon.
The U.S. Asthma and COPD Drugs Market Trends
In the North American region, US led the market owing to the rising incidence of chronic diseases, growing emphasis on personalized medicine, surge in technological advancements, and growing demand for point-of-care testing.
· In March 2024, the National Institute of Health and Care Research (NIHR) Patient Recruitment Center (PRC) at Bradford Teaching Hospitals recruited the first participants in Europe for two new clinical trials based on treating asthma and COPD. The trials AJAX Phase II and MIRANDA Phase III are led by AstraZeneca.
Increasing Healthcare Expenditures: Asian Countries to Boom
The Asia Pacific region is expected to grow at the fastest rate over the forecast period. The growth of the region can be credited to the increasing number of hospitals in emerging economies like China and India coupled with the rising healthcare expenditures in this country. Furthermore, increasing awareness regarding COPD and asthma among the majority of people in the region is attracting a large patient pool towards the treatment of this disease.
Immediate Delivery is Available | Get Full Report Access@ https://www.novaoneadvisor.com/report/checkout/7886
Related Report
· Asthma and COPD Drugs Market - https://www.precedenceresearch.com/asthma-and-copd-drugs-market
· Asthma Drugs Market - https://www.precedenceresearch.com/asthma-drugs-market
· U.S. Over the Counter (OTC) Drugs Market - https://www.precedenceresearch.com/us-over-the-counter-drugs-market
· Generic Drugs Market - https://www.precedenceresearch.com/generic-drugs-market
· HIV Drugs Market - https://www.precedenceresearch.com/hiv-drugs-market
Asthma and COPD Drugs Market Top Companies
· Pfizer Inc.
· Teva Pharmaceutical Industries Ltd.
· Merck & Co. Inc
· Grifols S.A.
· Novartis AG
· Cipla Inc.
· Abbott
· Astellas Pharma
· Hoffmann-La Roche Ltd
· Glenmark Pharmaceuticals
Asthma and COPD Drugs Market Recent Developments
· In May 2024, Blackstone announced the launch of the Blackstone Life Sciences portfolio company Uniquity Bio, a clinical-stage drug development company focused on immunology and inflammation. Uniquity Bio is emerging from stealth with an FDA acceptance of its Phase 2 investigational new drug application for solrikitug, a monoclonal antibody targeting TSLP, and up to $300 million in capital from Blackstone to advance the asset in multiple indications.
· In May 2024, Blackstone launched an Immunology Startup With $300M and a Phase 2-Ready Drug from Merck. Blackstone Life Sciences startup Uniquity Bio emerged from stealth with an in-licensed drug candidate that could treat a wide range of immunology and inflammation indications. The antibody's target puts it in competition with drugs from AstraZeneca, Pfizer, and Sanofi.
· In July 2023, Viatris Inc., a global healthcare company, and Kindeva Drug Delivery L.P. announced the launch of Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the first generic version of AstraZeneca's Symbicort® with an Abbreviated New Drug Application (ANDA) approved by the U.S. Food and Drug Administration (FDA).
· In July 2023, Drug firm Lupin launched a pressurized metered dose inhaler for the treatment of asthma and chronic obstructive pulmonary disease (COPD) in Germany. Hormosan Pharma GmbH, a wholly owned subsidiary of the company in Germany, has introduced Luforbec in the European nation.
Segment Covered in the Report
· Diseases Outlook
· Asthma
· COPD
By Medication Class Outlook
· Combination Drugs
· Bronchodilators
· Inhaled Corticosteroids (ICS)
· Short Acting Beta Agonists (SABA)
· Long-Acting Beta Agonists (LABA)
· Leukotriene Antagonists (LTA)
· Anticholinergics
· Anti-Inflammatories
· Others
By Regional Outlook
· North America
· Europe
· Asia Pacific
· Latin America
· Middle East and Africa (MEA)
Immediate Delivery Available | Buy This Premium Research https://www.novaoneadvisor.com/report/checkout/7886
USA: +1 804 441 9344
APAC: +61 485 981 310 or +91 87933 22019
Europe: +44 7383 092 044
Email: sales@novaoneadvisor.com
Web: https://www.novaoneadvisor.com/
You can place an order or ask any questions, please feel free to contact at sales@novaoneadvisor.com | +1 804 441 9344
